eturbonews

New Controlled Release Ophthalmic Eye Drop Product

DelSiTech Ltd. today announced an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech™ Silica Matrix technology. Dexamethasone ...
FiercePharma

Seeking to shake up eye inflammation market, Optifye and DelSiTech partner on controlled-release drops

Optifye Therapeutics has struck a deal with DelSiTech for controlled-release dexamethasone eye drops. The exclusive license agreement covers a candidate that uses DelSiTech Silica Matrix technology to ...
Healio

OCS-01 eye drop for DME in second stage of phase 3 trial

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. PARK CITY, Utah — Stage one of the phase 3 DIAMOND trial ...
Seeking Alpha

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society ...

OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive Surgery (ASCRS) while topline readout from the second Phase 3 OPTIMIZE-2 ...
Healio

Innovations in sustained-delivery options: Focus on postoperative treatment

Please provide your email address to receive an email when new articles are posted on . This two-part series reviews innovative sustained-delivery options for both long- and short-term indications.
Business Wire

Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching ...

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for ...